8.11

6.71% 0.51

Abcellera Biologics Inc (ABCL)

Overview News Price History Option Chain Financials Why ABCL Down? Discussions Forecast

Abcellera Biologics Inc stock is traded at $8.11, with a volume of 8.44M. It is up +6.71% in the last 24 hours and up +32.30% over the past month. AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.

Previous Close:

$7.60

Open:

$7.66

24h Volume:

8.44M

Relative Volume:

1.18

Market Cap:

$2.48B

Revenue:

$79.21M

Net Income/Loss:

$-143.96M

P/E Ratio:

-16.91

EPS:

-0.4796

Net Cash Flow:

$-189.60M

1W Performance:

+21.77%

1M Performance:

+32.30%

6M Performance:

+136.44%

1Y Performance:

+116.27%

1-Day Range:

$7.56

$8.32

1-Week Range:

$6.47

$8.42

52-Week Range:

$2.745

$8.42

Abcellera Biologics Inc Stock (ABCL) Company Profile

Name

Abcellera Biologics Inc

Sector

Healthcare (1098)

Industry

Biotechnology (615)

Phone

(604) 559-9005

Address

150 W 4TH AVENUE, VANCOUVER

Employee

562

Twitter

Next Earnings Date

2026-08-06

Latest SEC Filings

ABCL's Discussions on Twitter

Compare ABCL vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ABCL Abcellera Biologics Inc	8.11	2.40B	79.21M	-143.96M	-189.60M	-0.4796
VRTX Vertex Pharmaceuticals Inc	528.04	126.07B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	654.27	65.37B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	939.68	57.70B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	312.78	40.19B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	189.24	39.82B	742.00K	-1.37B	-1.07B	-7.0731

Abcellera Biologics Inc Stock (ABCL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-07-25	Downgrade	Leerink Partners	Outperform → Market Perform
Jul-07-25	Resumed	Leerink Partners	Outperform
Aug-20-24	Downgrade	The Benchmark Company	Buy → Hold
Feb-22-24	Upgrade	The Benchmark Company	Hold → Buy
Dec-05-23	Initiated	KeyBanc Capital Markets	Overweight
Nov-06-23	Downgrade	The Benchmark Company	Buy → Hold
Oct-13-23	Resumed	Piper Sandler	Overweight
Feb-28-23	Initiated	Cowen	Outperform
Dec-15-22	Initiated	Goldman	Buy
Nov-16-22	Initiated	Truist	Buy
Dec-21-21	Initiated	The Benchmark Company	Buy
Nov-19-21	Initiated	Piper Sandler	Overweight
Jan-05-21	Initiated	BMO Capital Markets	Outperform
Jan-05-21	Initiated	Berenberg	Buy
Jan-05-21	Initiated	Credit Suisse	Outperform
Jan-05-21	Initiated	SVB Leerink	Outperform
Jan-05-21	Initiated	Stifel	Buy

View All

Abcellera Biologics Inc Stock (ABCL) Latest News

Jul 01, 2026

Is AbCellera Biologics (ABCL) One of the Best Stocks with Biggest Upside? - Yahoo Finance

Jul 01, 2026

ABCL Stock Clocks Best Week Since February On Clinical Data Anticipation, Baker Bros Stake Boost - Stocktwits

Jul 01, 2026

Jun 29, 2026

ABCL News | ABCELLERA BIOLOGICS INC (NASDAQ:ABCL) - ChartMill

Jun 29, 2026

ABCL Jumps As Jazz Deal Fuels Antibody Pipeline Momentum - StocksToTrade

Jun 29, 2026

AbCellera Biologics Stock (ABCL) Opinions on Recent Technical Breakout and Pipeline Progress - Quiver Quantitative

Jun 29, 2026

Jun 28, 2026

Why Did SLS, MRNA, ABCL Stocks Surge To 52-Week Highs Last Week? - Stocktwits

Jun 28, 2026

Jun 27, 2026

ABCELLERA BIOLG (ABCL) Surges 7.1%: Is This an Indication of Further Gains? - MSN

Jun 27, 2026

Enterprise value to revenue forward of AbCellera Biologics Inc. – NASDAQ:ABCL - TradingView

Jun 27, 2026

Jun 26, 2026

Enterprise value to EBIT forward of AbCellera Biologics Inc. – NASDAQ:ABCL - TradingView

Jun 26, 2026

AbCellera Biologics(ABCL) Stock Options Chain | Quotes & News - Moomoo

Jun 26, 2026

Price to sales forward of AbCellera Biologics Inc. – NASDAQ:ABCL - TradingView

Jun 26, 2026

Price to earnings forward of AbCellera Biologics Inc. – NASDAQ:ABCL - TradingView

Jun 26, 2026

JonesTrading Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Maintains Target Price $13 - Moomoo

Jun 26, 2026

Jun 25, 2026

Abcellera Biologics stock hits 52-week high at 6.79 USD By Investing.com - Investing.com Nigeria

Jun 25, 2026

Jazz Pharmaceuticals (JAZZ) Expands AbCellera Tie Up As Zepzelca Trial Misses Goal - Yahoo Finance

Jun 24, 2026

Jun 23, 2026

Jazz Pharmaceuticals and AbCellera Biologics Inc. (ABCL) Announce Collaboration - Insider Monkey

Jun 23, 2026

Jun 22, 2026

12 Best AI Drug Discovery Stocks Hedge Funds Are Loading Up On - Insider Monkey

Jun 22, 2026

Are Medical Stocks Lagging ABCELLERA BIOLG (ABCL) This Year? - MSN

Jun 22, 2026

Jun 21, 2026